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The common fragile site, FRA3B, has been shown to be a site of frequent homozygous deletions in some cancers, resulting
in loss of expression of the associated FHIT gene. It has been proposed that FHIT is a tumor suppressor gene that is inactivated
as a result of the instability of FRA3B in tumorigenesis. More recently, deletions at other common fragile sites, FRA7G and
FRA16D, have been identified in a small number of cancer cell lines. Here, we have mapped and molecularly characterized the
frequently observed common fragile site FRAXB, located at Xp22.3. Like other common fragile sites, it spans a large genomic
region of approximately 500 kb. Three known genes, including the microsomal steroid sulfatase locus (STS), map within the
fragile site region. We examined FRAXB and four other fragile sites (FRA3B, FRA7G, FRA7H, FRA16D), and several associated
genes, for deletions and aberrant transcripts in a panel of cancer cell lines and primary tumors. Deletions within FRAXB were
seen in 4/27 (14.8%) of the primary tumors and cell lines examined. Three of the 21 (14.3%) cell lines examined were
characterized by loss of expression of one or more FRAXB-associated genes. Moreover, all of the fragile sites examined were
characterized by genomic deletions within the fragile site regions in one or more tumors or cell lines, including FRAXB, which
is not associated with any known tumor suppressor genes or activity. Our results further support the hypothesis that common
fragile sites and their associated genes are, in general, unstable in some cancer cells. © 2002 Wiley-Liss, Inc.
INTRODUCTION
Chromosome fragile sites are loci that are “hot
spots” for gaps and breaks on metaphase chromo-
somes when DNA synthesis is perturbed (reviewed
in Glover, 1998). There are two classes of fragile
sites, rare and common. Common fragile sites are
expressed when cells are grown under conditions
that inhibit DNA synthesis, such as folate defi-
ciency or with aphidicolin, a specific inhibitor of
DNA polymerases. They are seen in all individuals
and represent a basic component of chromosome
structure that is poorly understood. At least 80
common fragile sites exist, with at least one found
on most human chromosomes.
Common fragile sites have been proposed to
play a mechanistic role in chromosome transloca-
tions and other rearrangements in cancer cells in
vivo, based on their behavior in vitro and their
colocalization with chromosome breakpoints in
vivo. In vitro, they have been shown to display
characteristics of unstable and highly recombino-
genic DNA, consistent with the hypothesis that
fragile site gaps can lead to DNA double-strand
breaks. After induction, these sites show increased
sister-chromatid exchange on metaphase chromo-
somes and a high rate of deletions and transloca-
tions in somatic cell hybrid systems (reviewed in
Glover, 1998). In addition, it has been shown that
breaks at fragile sites can trigger and set boundaries
to gene amplification events in CHO cells (Co-
quelle et al., 1997).
Most information about the biological behavior
of common fragile sites in vivo comes from the
study of FRA3B, the most frequently seen fragile
site on human metaphase chromosomes. It maps to
a region of 3p known to be associated with dele-
tions in a number of solid tumors (Glover et al.,
1988; Hibi et al., 1992; Negrini et al., 1996) and
spans the t(3;8) breakpoint segregating in a family
with hereditary renal cell carcinoma (Glover et al.,
1988; Huebner et al., 1997). FRA3B maps to the
same region as the FHIT gene (Ohta et al., 1996;
Wilke et al., 1996; Huebner et al., 1997). The FHIT
gene spans an estimated 900–1,000 kb of 3p14.2.
In contrast to its large genomic size, it encodes only
a 1.1 kb transcript, the product of which is a hy-
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drolase involved in the cleavage of diadenosine
triphosphates (Barnes et al., 1996). FRA3B maps in
a region extending at least from FHIT intron 4
through part of the very large intron 5, a distance of
about 500 kb (Ohta et al., 1996).
The FHIT gene has been shown to be fre-
quently deleted and to produce aberrant transcripts
in a large number of tumor types (Negrini et al.,
1996; Ohta et al., 1996; Sozzi et al., 1996; Druck et
al., 1997; Michael et al., 1997). The FHIT protein
was shown to be absent or reduced in cell lines
harboring homozygous or hemizygous deletions
(Druck et al., 1997). The deletions frequently span
hundreds of kilobases and largely occur within
FRA3B. In addition, at least four translocations
with breakpoints in FHIT/FRA3B have been re-
ported (Ohta et al., 1996; Geurts et al., 1997; Fang
et al., 2001). These findings are consistent with the
hypothesis that FRA3B is unstable in some cancer
cells and is mechanistically involved in the chro-
mosome rearrangements. Based largely on the oc-
currence of frequent homozygous deletions, it was
suggested that FHIT is a frequently inactivated
tumor suppressor gene (Ohta et al., 1996). Whereas
subsequent studies have left some doubt about the
role of FHIT as a tumor suppressor gene (Otterson
et al., 1998; Wu et al., 2000), recent functional
studies have provided support for this view (Si-
prashvili et al., 1997; Fong et al., 2000; Dumon et
al., 2001).
A number of possibilities exist to account for the
frequent deletions of the FHIT gene in tumors.
First, the frequent FHIT deletions may be inde-
pendent of FRA3B and are selected for during
tumorigenesis. Second, the deletions may be
caused by instability at FRA3B and, again, selected
for due to the tumor suppressor function of FHIT.
Third, the deletions may be caused by fragile site
instability in certain tumor cells and are maintained
without selection. The latter two possibilities in-
voke a mechanism of fragile site instability in cer-
tain cancer cells. If this is true, it would suggest
that additional common fragile sites are also unsta-
ble in cancer. Limited data exist that directly ad-
dress this question. Homozygous deletions have
been observed in a small number of tumors at other
fragile sites, including FRA7G in ovarian cancer
and FRA16D in gastric adenocarcinoma and mul-
tiple myeloma, suggesting that common fragile
sites are generally unstable and may lead to gene
inactivation in cancer cells (Huang et al., 1999;
Mangelsdorf et al., 2000). It is unclear whether
these deletions represent generalized fragile site
instability in cancer or simply a selective event that
coincidentally includes fragile site loci.
Examining tumors for deletions and gene inac-
tivation at other fragile sites is one way to provide
insight into the mechanisms of fragile site instabil-
ity and the role of FHIT as a tumor suppressor
gene. In this article, we define the location, bound-
aries, and known genes associated with FRAXB, a
frequently observed common fragile site that has
not been associated with any known tumor sup-
pressor gene locus. We examined the stability of
FRAXB, its associated genes, and additional com-
mon fragile sites FRA7G, FRA7H, and FRA16D in
a panel of cancer cell lines. Our results support the
hypothesis that fragile sites, in general, are sites of
frequent deletion in some cancer cells.
MATERIALS AND METHODS
FISH
Fluorescence in situ hybridization (FISH) was
performed on metaphase cells from peripheral
blood lymphocytes treated with 0.3 mM aphidicolin
to induce common fragile sites. As previously de-
scribed (Dagenais et al., 1999), metaphase chromo-
some slides were denatured and then hybridized
overnight with biotin-14-dATP-labeled probes. A
BioNick Translation Kit (Gibco BRL, Gaithers-
burg, MD) was used to label probes from yeast
artificial chromosome (YAC), bacterial artificial
chromosome (BAC), and cosmid clones. Prior to
hybridization, probes were denatured for 8 min at
70°C and preannealed for 30–60 min at 37°C with
human Cot1 DNA (Gibco BRL). FISH signals
were visualized by incubation with two layers of
fluorescein isothiocyanate (FITC)-conjugated avi-
din-DCS (Vector Laboratories, Burlingame, CA)
and fluorescein-conjugated anti-avidin IgG. Chro-
mosomes were counterstained with 49,6-diamidino-
2-phenylindole (DAPI, Vector Laboratories). FISH
results were analyzed with a Zeiss Axioscop epiflu-
orescence microscope.
Cell Lines and Tissue Specimens
Esophageal adenocarcinoma tissue samples were
obtained from patients undergoing surgical resec-
tion at the University of Michigan hospital. Con-
sent was received from all patients, and the project
was approved by the Institutional Review Board
(Medicine). All patient identifiers were removed.
Tumor specimens were frozen in liquid nitrogen
and stored at 270°C. Primary tumor samples ana-
lyzed were M60, P16, F93, S45, D01, and L86. A
panel of 21 cancer cell lines was also used in these
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experiments. These cell lines were derived from
breast (HCC1937, SUM149, SUM159, SUM44,
SUM102, SUM185, SUM190, SUM225, SUM229,
SUM1315M02), cervical (HeLa, SiHa, CASKI,
and CC-19), colon (HT-29, SW-480, LS180), gas-
tric (KATOIII), and esophageal (BIC-1, FLO-1,
SEG-1) carcinomas.
DNA/RNA Extractions
DNA was isolated from fresh tissue by standard
proteinase K digestion and phenol extraction as
previously described (Sambrook et al., 1989). Cell
line DNA was isolated from confluent T75 flasks
using the QIAamp Tissue Kit (Qiagen, Valencia,
CA). Cell line total RNA was extracted from sub-
confluent T75 flasks using Trizol according to the
manufacturer’s instructions (Gibco BRL).
Reverse-Transcription Polymerase Chain
Reaction (RT-PCR)
Five micrograms of total RNA was reverse tran-
scribed in a total volume of 20 ml using an oligo-(dT)
primer and the Superscript II Reverse Transcriptase
(Gibco BRL) according to the manufacturer’s instruc-
tions. Four microliters of the RT reaction was used
for one round of PCR amplification consisting of 30
cycles at 94°C for 1 min, annealing temperature for 1
min, and 72°C for 3 min. The primers used to amplify
FHIT transcripts were an exon 1 specific primer,
6159E (59-CATCCTGGAAGCTTTGAAGCTCA-
39), and an exon 10 specific primer, 8243I (59-CAT-
GCTGATTCAGTTCCTCTTGG-39). An anneal-
ing temperature of 56°C was used. The primers used
to amplify the ATP7A transcript were an exon 3 spe-
cific primer, 64C (59-GTCAGGAGCTTGTGAA-
GATCA-39), and an exon 20 specific primer, 75C
(59CCCACATTAGCCATTGCCAGA-39). An an-
nealing temperature of 60°C was used. The STS
transcript was amplified at an annealing temperature
of 63°C using an exon 2 specific primer, 5691I (59-
TTTCTGTGGGAAGCCGAGAG-39), and an exon
10 specific primer, 3875I (59-TGCTGAGGGGT-
GAGTTAAGG-39). GS1 was amplified at an anneal-
ing temperature of 58°C using an exon 1 specific
primer, 2707J (59-CTCATCTTTGACATGGAC-
GG-39), and an exon 4 specific primer, 2706J (59-
CAGACATATATTCAGGCCATCAAG-39). TLR5a
was amplified using an annealing temperature of
55°C with an exon 1 specific primer, 2705J (59-
CTCGCGGAGAGCGTAGC-39), and an exon 7 spe-
cific primer, 2704J (59-CAATTTAAGGGTACAT-
CAACAAGG-39). With the exception of the FHIT
RT-PCR reactions, all reactions were carried out us-
ing the Expand Long Template PCR System
(Roche, Indianapolis, IN). FHIT was amplified using
standard Taq polymerase (Gibco BRL).
PCR products were analyzed on 1% agarose gels
and visualized by staining with ethidium bromide.
The products in the gel were then transferred to
nylon membranes and hybridized with 32P-labeled
cDNA probes specific to each reaction. Probes
were labeled using the Random Primers Labeling
Kit (Gibco BRL). Membranes were exposed to
BioMax MS film (Eastman Kodak, Rochester, NY).
Genomic PCR
Genomic DNA was used as template for PCR
with 25 markers from several common fragile sites.
Markers from FRA3B were D3S2977, D3S4103,
D3S1481, and FHIT exon 5 (forward 59-TCATTT-
GGCTGGTTAGGCTC-39; reverse 59-AATGGC-
ATCCTCTCTGCAAC-39). Markers from FRA7G
were D7S486, 7G2, and 7G14 (Huang et al., 1999).
Markers from FRA7H were WI-16323 and D7S649.
Markers from FRAXB were DXS6701, DXS1130,
DXS1133,DXS1407,STSexon2(forward59-TTTC-
TGTGGGAAGCCGAGAG-39; reverse 59-GGTTT-
GGAGGGTTTTGAACG-39), and STS exon 10 (for-
ward 59-CCAACACGCCTGAGAGTGGC-39; re-
verse 59-TGCTGAGGGGTGAGTTAAGG-39).
Control markers were D3S3577, D3S4483, D7S500,
DXS8079, KAL intron 13 (forward 59-GACCCAAG-
TCCACCTACTTC-39; reverse 59-TATCAAGCT-
CTCCCATTGTG-39), and ATP7A exon 4 (forward
59-TTCATCTTATCTCAGTAGAGG-39; reverse
59-TACTACCAACGGCTCATTCGT-39).
Markers were amplified with Taq DNA polymer-
ase (Gibco BRL) in reactions containing 1.5 mM
MgCl2, 0.2 mM dNTPs, 0.1 mM each primer, and
100 ng of template DNA. When a marker failed to
amplify in a sample in two consecutive PCR reac-
tions, multiplex PCR was performed using the
marker in question and a proven control marker.
Reaction conditions were essentially the same as
above, but we used 1.4 mM dNTPs and 4 mM
MgCl2. PCR products were analyzed on 1% aga-




To determine precisely the location and bound-
aries of FRAXB, we performed FISH with ordered
YAC clones from Xp22. One YAC, 933D4, was
found to cross the fragile site on metaphase chro-
mosomes from peripheral-blood lymphocytes
treated with aphidicolin. These results indicate
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that FRAXB colocalizes with this clone. However,
on some metaphase chromosomes, 933D4 hybrid-
ized either proximal or distal to the fragile site
break, indicating that FRAXB extends beyond the
boundaries of this YAC clone.
To determine the size and boundaries of
FRAXB more accurately, we performed additional
FISH experiments with a panel of YAC, BAC, and
cosmid clones that map distal or proximal to YAC
933D4. We quantitated the number of times each
clone hybridized proximal to, crossing, or distal to
the fragile-site break. These data are summarized
in Table 1. Three cosmid clones, 3G1, 19C7, and
87B11, were found to map exclusively distal to
FRAXB, whereas an overlapping cosmid, 74A4,
frequently crossed the break in addition to map-
ping distal to it. These data indicate that the distal
boundary of FRAXB is near DXS1130, a marker
shared by 87B11 and 74A4 (Fig. 1A).
In addition to YAC 933D4 and cosmid 74A4,
several clones were found to cross FRAXB. These
clones include cosmid 37D9, YACs 29C11 and
29G1, and BAC 146L1. These clones represent the
core of FRAXB and span from DXS1130 proxi-
mally past DXS1131.
Two overlapping BAC clones, 388M15 and
542P7, hybridized proximal to the fragile site on
metaphase chromosomes. These clones contain
DXS237 and DXS1132, respectively, and represent
the proximal boundary of FRAXB. Based on these
data the proximal boundary is positioned between
DXS1133 and DXS237. Like FRA3B, FRAXB is a
very large fragile site, spanning approximately 500
kb of genomic sequence as defined by the location
of gaps and breaks on metaphase chromosomes.
Approximately 235 kb of FRAXB have been
sequenced from overlapping BACs GSHB-227L7
(GenBank accession no. AC005704) and RP11-
483M24 (GenBank accession no. AC073583). This
sequence is composed of 57.7% A and T. Much of
the sequence contains repeat elements, including
Alu (9.2%), Mir (0.6 %), L1 (8.3%), L2 (1.1%), and
long terminal repeat (LTR) (10.2%) elements.
The LTRs in this sequence include six human
endogenous retrovirus-like (HERV-L)-derived se-
quences. In addition, the sequence contains simple
di- and tetranucleotide repeats such as (CA)n, (TA-
GA)n, and (GGAA)n. Approximately 301 kb of se-
quence from overlapping BACs GSHB-214D18
(GenBank accession no. AC005296) and RP11-
143E20 (GenBank accession no. AC074034) is also
available just proximal to FRAXB. BAC clone
TABLE 1. Identification of Cosmid, BAC, and








3G1 15 0 0 Distal
19C7 7 0 0 Distal
87B11 12 0 0 Distal
74A4 8 5 1 Crossing
YAC933D4 13 6 4 Crossing
YAC29C11 4 2 4 Crossing
37D9 5 6 2 Crossing
YAC29G1 4 3 4 Crossing
BAC146L1 9 3 5 Crossing
BAC388M15 0 0 15 Proximal
BAC542P7 0 1 16 Proximal
aNumber of metaphase cells in which FISH signal was located distal to
the fragile-site break.
bNumber of metaphase cells in which FISH signal was divided across the
fragile-site break.
cNumber of metaphase cells in which FISH signal was located proximal
to the fragile-site break.
Figure 1. Genomic organization of FRAXB at Xp22.3. A: Determi-
nation of extent of FRAXB by FISH analysis. Markers from Xp22.3 are
arranged from distal (left) to proximal (right). The position of the fragile
site is indicated at the top. Horizontal lines represent cosmid, BAC, and
YAC clones used as FISH probes. Striped lines indicate clones that
hybridized distal to the fragile site. Solid black lines indicate clones that
hybridized across the fragile site break. Gray lines indicate clones that
hybridized proximal to the fragile site. B: Positions of genes in the
FRAXB region. The position of the fragile site is indicated at the top.
GS1 contains four exons near the distal boundary of FRAXB. STS
contains 10 exons near the center of FRAXB. A third gene, TLR5a,
contains seven exons positioned just proximal to FRAXB. Arrows
indicate the direction of transcription.
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214D18 overlaps the BAC 542P7 used in our map-
ping studies. This adjacent sequence contains low
to moderate amounts of Alu (4.5%), Mir (1.9%), L1
(7.5%), and L2 (2.4%) sequences. It is also charac-
terized by a high proportion of LTRs (11.8%), the
majority of which are of retroviral origin, including
two HERV-L-derived sequences.
Identification of Genes in the FRAXB Region
Several genes have been identified that map
within FRAXB. A gene of unknown function, GS1,
was identified in the distal third of FRAXB. It
consists of four exons spanning approximately 105
kb with a predicted transcript of 2.1 kb (Yen et al.,
1992). The microsomal steroid sulfatase (STS) gene
had been previously cloned and mapped to Xp22.3
(Ballabio et al., 1987; Mohandas et al., 1987; Yen et
al., 1987). The STS gene contains 10 exons span-
ning 146 kb. Alternative polyadenylation signals in
exon 10 generate transcripts of 2.7 kb, 5.2 kb, and
7.0 kb in a tissue-specific manner (Yen et al., 1988).
The STS gene is inactivated in X-linked icthyosis,
primarily through large deletions. Both STS and
GS1 were localized in a contig that maps to the
FRAXB region (Lee et al., 1993). A third gene
encoding the Toll-like receptor 5a (TLR5a) was
identified at a CpG island just proximal to the
fragile site (Lee et al., 1994). It contains seven
exons spanning 28.6 kb that encode a 2.8 kb tran-
script. The positions of these genes relative to
FRAXB are depicted in Figure 1B.
Genes at FRAXB Are Inactivated in Cancer Cells
As one measure of gene deletion and aberrant
transcription, expression of the genes that colocal-
ize with FRAXB (STS, GS1, TLR5a) was examined
in a panel of 21 cancer cell lines and one normal
fibroblast control by RT-PCR and subsequent
Southern blot hybridization of products. Because of
the high frequency of deletion at FRA3B, expres-
sion of the FHIT gene was examined as a positive
control for loss of expression and production of
aberrant transcripts. The Menkes disease gene
(ATP7A) at Xq13, which produces an RT-PCR
product comparable in size to the FRAXB-associ-
ated genes, was used as a negative control.
STS was amplified using primers in exon 2 and in
exon 10 upstream of the various polyadenylation
signals to ensure that all of the possible transcripts
could be detected. No aberrant transcripts were
observed in any FRAXB-associated genes. How-
ever, these experiments revealed that STS and GS1
transcripts were absent in two cell lines, BIC-1
(esophageal) and SW-480 (colon). TLR5a was no
longer expressed in one cell line, 1315M02 (breast).
Overall, 14.3% (3/21) of the cell lines had lost
expression of one or more genes in the FRAXB
region (Table 2). The BIC-1 cell line had previ-
ously been karyotyped and found to be disomic for
the X chromosome (Fang et al., 2001). The
1315M02 breast cancer cell line was karyotyped
and found to have the expected two copies of the
X chromosome. SW-480 is a colon cancer cell line
with a chromosome modal number of 55 derived
from a male patient (Leibovitz et al., 1976).
No FHIT transcript was detected in 19.0% (4/21)
of the cell lines. Five cell lines (23.8%) had only
aberrant FHIT transcript. An aberrant FHIT tran-
script in the presence of a normal FHIT transcript
was seen in one cell line (4.8%). In total, 10/21
(47.6%) of the tumor cell lines were characterized
by an alteration of FHIT expression.
An ATP7A PCR product of the expected size was
seen in all cell lines examined. A summary of the
gene expression data is shown in Table 3. Repre-
sentative examples of RT-PCR data are shown in
Figure 2A.
Homozygous and Hemizygous Deletions
at Common Fragile Sites
The occurrence of homozygous or hemizygous
deletions was examined in a panel of primary tu-
mors and cancer cell lines to determine if se-
quences at common fragile sites are, in general,
especially prone to deletions in cancer cells.
Genomic PCR was performed on 21 cancer cell
lines and six primary esophageal adenocarcinomas
using markers from five common fragile sites:
FRA3B (four markers), FRA7G (four markers),
FRA7H (two markers), FRA16D (four markers),
and FRAXB (six markers). Six markers from non-
fragile site regions were also included as controls.
These controls included two markers at 3p14, one
marker at 7q31, one marker at Xp22.3, and two
markers at Xq13. Whenever a marker failed to










ATP7A None Xq13 0/21 0.0
FHIT FRA3B 3p14 9/21 42.9
GS1 FRAXB Xp22 2/21 9.5
STS FRAXB Xp22 2/21 9.5
TLR5a FRAXB Xp22 1/21 4.8
Xp22 genes FRAXB Xp22 3/21 14.3
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amplify through two separate rounds of PCR, mul-
tiplex PCR was performed with a second marker to
confirm the reliability of the DNA, PCR reagents,
and conditions. Representative examples of multi-
plex PCR showing deletions are illustrated in Fig-
ure 2B.
Every fragile site was characterized by homozy-
gous deletion in at least one tumor or cell line. The
most frequent deletions were observed at markers
from FRA3B, with 6/27 (22.2%) samples demonstrat-
ing homozygous deletions in at least one marker in
this fragile site. FRAXB was characterized by dele-
tions in 4/27 (14.8%) of samples. FRA16D was ho-
mozygously deleted in 3/27 (11.1%) specimens.
FRA7G and FRA7H were each homozygously de-
leted in 1/27 (3.7%) of the samples (Tables 3, 4).
None of the samples had homozygous deletions at
any of the control markers or at loci flanking FRA3B
and FRAXB. Overall, 33.3% (9/27) of the tumors and
cell lines were characterized by homozygous dele-
tions of sequences from at least one fragile site. Three
of the specimens (11.1%) had deletions at more than
one fragile site. One cell line, BIC-1, had homozy-
gous deletions at FRA3B, FRA16D, and FRAXB. A
second cell line, SW-480, had deletions at FRA3B
and FRAXB. One of the primary esophageal adeno-
carcinomas, S45, had deletions at FRA7G, FRA7H,
FRA16D, and FRAXB. Two of the deletions at
FRAXB occurred in cell lines that were included in
the gene expression analyses, BIC-1 and SW-480. In
both cases, deletion of FRAXB sequences correlated
with loss of expression of STS and GS1. A summary of
the homozygous deletion data is shown in Table 3.
Deletion Breakpoints Colocalize With
Fragile-Site Boundaries
In several cases, deletion breakpoints colocalized
with the established boundaries of the fragile sites.
As mentioned previously, the distal boundary of
FRAXB is at DXS1130 and the proximal boundary
TABLE 3. Summary of Gene Expression and Homozygous Deletion Data
Cell line Sexa Typeb
Gene expressionc Homozygous deletiond
FHIT GS1 STS TLR5a ATP7a FRAXB FRA3B FRA7G FRA7H FRA16D
BIC-1 M Esophagus ● ● ● 1 1 ● ● 1 1 ●
FLO-1 M Esophagus ● 1 1 1 1 1 1 1 1 ●
SEG-1 M Esophagus 1 1 1 1 1 1 ● 1 1 1
KATOIII M Gastric ● 1 1 1 1 1 ● 1 1 1
HT-29 F Colon ● 1 1 1 1 1 ● 1 1 1
SW480 M Colon 1 ● ● 1 1 ● ● 1 1 1
LS180 F Colon 1 1 1 1 1 1 1 1 1 1
HeLa F Cervix ● 1 1 1 1 1 1 1 1 1
SIHA F Cervix ● 1 1 1 1 1 1 1 1 1
CASKI F Cervix 1 1 1 1 1 1 1 1 1 1
CC-19 F Cervix ● 1 1 1 1 1 ● 1 1 1
HCC1937 F Breast 1 1 1 1 1 1 1 1 1 1
SUM149 F Breast ● 1 1 1 1 1 1 1 1 1
SUM159 F Breast 1 1 1 1 1 1 1 1 1 1
SUM44 F Breast ● 1 1 1 1 1 1 1 1 1
SUM102 F Breast 1 1 1 1 1 1 1 1 1 1
SUM185 F Breast 1 1 1 1 1 1 1 1 1 1
SUM190 F Breast 1 1 1 1 1 1 1 1 1 1
SUM225 F Breast 1 1 1 1 1 1 1 1 1 1
SUM229 F Breast 1 1 1 1 1 1 1 1 1 1
SUM1513M02 F Breast 1 1 1 ● 1 1 1 1 1 1
M60e M Esophagus ND ND ND ND ND 1 1 1 1 1
P16e M Esophagus ND ND ND ND ND 1 1 1 1 1
F93e M Esophagus ND ND ND ND ND 1 1 1 1 1
S45e M Esophagus ND ND ND ND ND ● 1 ● ● ●
D01e M Esophagus ND ND ND ND ND 1 1 1 1 1
L86e M Esophagus ND ND ND ND ND ● 1 1 1 1
aM, male; F, female.
bTumor origin.
cGene expression determined by RT-PCR. “1” indicates normal expression, “●” indicates loss of normal transcript, “ND” indicates no data due to
unavailable RNA from primary tumors.
dHomozygous deletion determined by genomic PCR. “1” indicates no deletion, “●” indicates homozygous deletion.
ePrimary tumor.
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is between DXS1133 and DXS237. During the
course of the homozygous deletion studies, we dis-
covered that two tumor cell lines, BIC-1 and SW-
480, appear to have deletions of approximately the
same size at FRAXB. PCR with additional markers
revealed that these two cell lines indeed shared
similar deletion breakpoints. Furthermore, these
breakpoints colocalize with the boundaries of the
FRAXB fragile site, as determined by our FISH
studies (Fig. 3). Both cell lines have deletions at
DXS1130 but retain the next most distal marker
tested, DXS6701, indicating that the distal deletion
breakpoint is between these two markers. Simi-
larly, both cell lines have deletions at DXS1133 but
retain the next most proximal marker, DXS237.
These data indicate that the proximal deletion
breakpoint is between these two markers in these
cell lines. These deletions appear to remove se-
quences necessary for expression of FRAXB.
When BIC-1 cells were treated with aphidicolin to
induce fragile sites, no gaps or breaks were ob-
served at FRAXB in 100 metaphase cells, indicat-
ing that the deletion eliminated the site’s fragility.
Further analyses with the two primary esopha-
geal adenocarcinomas characterized by FRAXB de-
letions revealed that they share the same prox-
imal deletion boundary between DXS1133 and
DXS237. The proximal breakpoint of tumor L86 is
between DXS1133 and DXS1131, within the frag-








FRA3B D3S2977 0/27 (0.0%)
D3S4103 3/27 (11.1%) 6/27 (22.2%)
FHIT exon 5 3/27 (11.1%)
D3S1481 2/27 (7.4%)
FRA7G D7S486 0/27 (0.0%)
7G2 1/27 (3.7%) 1/27 (3.7%)
7G14 1/27 (3.7%)
FRA7H WI-16323 1/27 (3.7%) 1/27 (3.7%)
D7S649 0/27 (0.0%)
FRA16D D16S518 1/27 (3.7%)
WI-2755 2/27 (7.4%) 3/27 (11.1%)
AA398024 2/27 (7.4%)
D16S3029 1/27 (3.7%)
FRAXB* DXS6701 1/27 (3.7%)
DXS1130 3/27 (11.1%)
STS exon 2 3/27 (11.1%) 4/27 (14.8%)
STS exon 10 3/27 (11.1%)
DXS1133 4/27 (14.8%)
DXS1407 0/27 (0.0%)
Controls D7S500 (7q31) 0/27 (0.0%)
KAL intron 13 (Xp22.3) 0/27 (0.0%)
DXS8079 (Xq13) 0/27 (0.0%) 0/27 (0.0%)
ATP7A (Xq13) 0/27 (0.0%)
D3S3577 (3p14) 0/27 (0.0%)
D3S4483 (3p14.2) 0/27 (0.0%)
*Homozygous deletions or hemizygous deletions in cell lines or tumors
with one X chromosome.
Figure 2. Homozygous deletions and loss of gene expression at
common fragile sites in cancer cells. A: Examples of loss of gene
expression at FRAXB detected by RT-PCR. A control fibroblast and
seven cancer cell lines are indicated above each lane. The RT-PCR
products corresponding to STS, GS1, and TLR5a are shown in the first
three panels, respectively. The fourth panel shows RT-PCR results for
FHIT, containing both loss of gene product and aberrant transcripts. The
fifth panel contains products from ATP7A, a control. B: Examples of
homozygous deletions at common fragile sites detected by multiplex
PCR. A control fibroblast and seven cancer cell lines are indicated
above each lane. Representative PCR results revealing homozygous
deletions are shown for FHIT exon 5 (FRA3B), WI-2755 (FRA16D), and
STS exon 10 (FRAXB).
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ile site, whereas tumor S45 appears to have a ter-
minal deletion.
DISCUSSION
Structure and Composition of FRAXB
We have defined the boundaries of the common
fragile site FRAXB at Xp22.3, localizing this fragile
site to approximately 500 kb between DXS1130
and DXS237. The FRAXB region contains three
previously identified genes, STS, GS1, and TLR5a.
This region is currently being sequenced by the
Human Genome Sequencing Center at the Baylor
College of Medicine, and about 235 kb of sequence
data are available from within FRAXB (GenBank
Accession nos. AC005704 and AC073583). Addi-
tional sequence is available flanking the fragile site
boundaries. From the available data, FRAXB ap-
pears to be moderately A-T rich (57.7%) and con-
sists of approximately 31% interspersed repeat el-
ements. This repeat element content is slightly
lower than the 38.5% expected for DNA of this
A-T content (Smit et al., 1996). Sequence analysis
revealed that about 301 kb of sequence immedi-
ately proximal to FRAXB had a slightly higher A-T
content (61%) and a similar frequency of inter-
spersed repeats (32%). The proportions of long
terminal repeats, transposable elements, L2s, and
Mirs in the FRAXB sequence are similar to those
previously reported for FRA3B, FRA7H, and
FRA16D (Ried et al., 2000). There are differences
in the proportion of Alu and L1 elements seen in
FRAXB and other fragile sites. FRA3B and
FRA7H have a relatively high proportion of L1
sequences, 11.7% and 13.2%, respectively (Ried
et al., 2000). The FRAXB sequence contains a
slightly lower proportion of L1 sequences (8.3%).
FRA3B also has a fairly low Alu content of 6.3%.
The available sequence from FRAXB has a mod-
erate Alu content of approximately 9.2%. FRA16D
sequence contains 2.8% L1 and 13.8% Alu (Ried et
al., 2000). In these respects, from the sequence
currently available, FRAXB appears to fall be-
tween FRA3B and FRA16D in terms of repeat
content. It is noteworthy that the sequence imme-
diately proximal to FRAXB has a lower Alu content
of 4.5% and an L1 content of 7.5%.
Viral integration sites have been previously re-
ported at several common fragile sites. FRA3B is
associated with an HPV16 integration site that was
described in a primary cervical carcinoma (Wilke et
al., 1996). More recently, an endogenous HERV-H
sequence was identified at FRA7G (Huang et al.,
1998) and an SV40 integration site was found in
FRA7H (Mishmar et al., 1998). Our finding that
sequences from within FRAXB and just proximal
to the FRAXB proximal boundary as defined here
contain a high proportion of retroviral sequences,
including multiple HERV-L sequences, appears to
support the hypothesis that common fragile sites
are preferential sites of viral integration. Additional
sequence from within the fragile site is needed to
confirm this suggestion.
Deletions and Loss of Gene Expression
at Common Fragile Sites
Previous studies investigating fragile site stabil-
ity have shown frequent deletions at FRA3B in a
variety of cancers and cancer cell lines, including
lung, digestive tract, and breast cancer (Negrini et
al., 1996; Ohta et al., 1996; Sozzi et al., 1996; Druck
et al., 1997; Michael et al., 1997). Recently, ho-
mozygous deletions have been observed in tumors
at other fragile sites as well, including FRA7G in
ovarian cancer and FRA16D in gastric adenocarci-
noma and multiple myeloma, suggesting that com-
mon fragile sites are generally unstable and may
lead to gene inactivation in cancer cells (Huang et
al., 1999; Mangelsdorf et al., 2000). In addition,
translocations within fragile sites have been iden-
tified at FRA3B and FRA16D (Ried et al., 2000;
Fang et al., 2001). All of these alterations occur in
regions that have been previously implicated in
tumorigenesis, suggesting that increased genomic
instability during tumor development may lead to
preferential inactivation of genes at fragile sites and
a selective growth advantage when the inactivated
genes have tumor suppressor activity. FRAXB is
not associated with any known tumor suppressor
Figure 3. Colocalization of FRAXB boundaries and deletion break-
points in cancer cells. Markers from Xp22.3 are arranged from distal
(left) to proximal (right) with the position of FRAXB indicated at the
top. Deleted regions in two cancer cell lines (BIC-1 and SW-480) and
two primary esophageal adenocarcinomas (S45 T and L86 T) are indi-
cated with black bars underneath the deleted markers. Shaded areas
indicate the regions where the deletion breaks occur.
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activity, based on LOH studies and locations of
known tumor suppressor genes. In addition, 85% of
X-linked ichthyosis cases are due to inactivation of
STS through large deletions at Xp22 that include
FRAXB and large amounts of flanking sequence
(Ballabio et al., 1987; Gillard et al., 1987; Yen et al.,
1987). Patients with X-linked ichthyosis are not
characterized by tumor development, providing
further support that Xp22.3 is devoid of tumor
suppressor activity. While we cannot completely
rule out the possibility that an unknown tumor
suppressor gene may map to this region, or that a
selective advantage is conferred to cancer cells with
Xp22.3 deletions, it is likely that fragile site insta-
bility at FRAXB in cancer cells can be examined
without selection for deletion events.
As expected, a high frequency of deletions was
observed at FRA3B in our panel of cancer cell lines
and primary tumors. FRA3B is the most highly
expressed common fragile site under a variety of
conditions (Glover, 1998). Deletions were also
seen, at a somewhat lower frequency, at FRA7G,
FRA7H, FRA16D, and FRAXB. The relative fre-
quency of deletions at these fragile sites correlates
with the frequency at which these fragile sites are
generally expressed on metaphase chromosomes
(Glover et al., 1984). Homozygous deletions were
primarily seen in cells derived from esophageal and
colon tumors, with deletions rarely observed in
cervical cancer cell lines and never observed in
breast cancer lines. The fact that none of the non-
fragile site control markers and few of the se-
quences immediately flanking the fragile sites were
deleted suggests that these deletions are specific to
the fragile sites, and not simply the result of a
generalized genomic instability resulting in random
deletions. This hypothesis is also supported by the
three samples that were characterized by homozy-
gous deletions at multiple fragile sites. It should be
noted that additional small interstitial deletions
might have occurred in the fragile site in the re-
gions between the markers examined, as has been
found at FRA3B in various tumors and tumor cell
lines. As such, the deletion frequencies reported
here are likely an underestimate of the actual de-
letions occurring within fragile sites.
Aberrant FHIT transcripts, indicating deletions
and aberrant splicing, have been identified by RT-
PCR in numerous cancers, including lung, diges-
tive tract, and breast cancer (Negrini et al., 1996;
Ohta et al., 1996; Sozzi et al., 1996; Druck et al.,
1997; Michael et al., 1997). For example, our group
performed studies to investigate deletions in FHIT
in primary esophageal tumors and the relationship
of FHIT deletions to FRA3B. We concluded from
these studies that both aberrant splicing and
genomic deletions of FHIT are indeed frequently
seen in primary tumors and occur at an early stage,
consistent with a role for FHIT as a tumor suppres-
sor gene (Michael et al., 1997). We and others have
hypothesized that FHIT inactivation occurs as a
consequence of fragile site instability during tu-
morigenesis. One result of the deletions at FRAXB
in our cell lines is the loss of expression of associ-
ated genes, GS1 and STS. It is of note that, whereas
aberrant transcripts were frequently seen in FHIT,
they were never observed at any of the genes at
FRAXB. This is likely due to the sizes of these
genes and their positions relative to the fragile
sites. FHIT is a very large gene, spanning approx-
imately 1,000 kb of genomic DNA. FRA3B is com-
pletely contained within the gene, centered around
exon 5. Deletions at this fragile site can eliminate
exon 5 and surrounding sequences without abol-
ishing expression of the gene, resulting in aberrant
transcripts. Aberrant transcripts could also arise
during RNA processing of this large and complex
region. In contrast, the genes at FRAXB are rela-
tively small and are completely contained within
the fragile site boundaries. As a result, deletions at
FRAXB are likely completely to eliminate GS1
and/or STS expression rather than cause aberrant
transcripts. These data support the hypothesis that
common fragile site instability in cancer cells re-
sults in a loss of associated gene function due to
deletion events. If genes associated with specific
fragile sites, such as FHIT at FRA3B, have impor-
tant tumor suppressor functions, this generalized
fragile site instability can confer a growth advan-
tage on cells that have undergone fragile site dele-
tions. In the case of FRAXB, no known tumor
suppressor activity has been associated with the
region. Thus, a growth advantage conferred by
deletions in FRAXB is not known, but cannot be
ruled out completely.
Colocalization of Fragile Site and Deletion
Boundaries in Cancer Cells
Of the four samples that had homozygous dele-
tions at FRAXB, two had deletion breakpoints cor-
responding to the fragile site boundaries and the
other two had proximal deletion breakpoints at the
proximal boundary of FRAXB (Fig. 3). These co-
incident deletion/fragile site boundaries provide
further evidence for the preferential instability of
common fragile sites in cancer. The deletion
breakpoints seen in the BIC-1 esophageal cancer
cell line also provide insight into the mechanism of
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FRAXB fragility. The fragile site region appears to
be precisely deleted in this cell line, with little or
no flanking DNA deleted. This cell line no longer
displays fragility at Xp22.3, indicating that se-
quence is important for fragility, and that this nec-
essary sequence is found within the fragile site,
rather than being located proximal or distal to the
fragile site.
While the FRAXB region has not previously
been shown to be deleted in cancers, deletions in
another type of disorder have been reported. The
involvement of STS in X-linked icthyosis is un-
usual in that it is primarily inactivated through
large genomic deletions, rather than by point mu-
tations or small deletions (Yen et al., 1987). These
deletions are thought to arise through unequal mei-
otic recombination events between a family of
genes known as VCX (variably charged, X-chromo-
some mRNA on CRI-232) on Xp that is highly
conserved (Knowlton et al., 1989; Yen et al., 1990;
Fukami et al., 2000; Lahn et al., 2000). It is un-
likely that the conserved FRAXB deletions ob-
served in our primary tumors and cancer cell lines
are due to somatic recombination between mem-
bers of this family. Several published reports de-
scribe deletions in X-linked icthyosis caused by
VCX recombination. The deletions attributed to
these recombination events have breakpoints distal
to DXS6701 and proximal to DXS237, two markers
retained in our specimens (Yen et al., 1990; Fukami
et al., 2000). In addition, none of the VCX genes
mapped to Xp22.3 are localized within FRAXB.
In summary, we have localized and defined the
boundaries and genes associated with the common
fragile site FRAXB. This fragile site spans approx-
imately 500 kb of A–T-rich DNA. The repeat el-
ement content determined by analysis of available
sequence reveals that FRAXB more closely resem-
bles FRA16D than either FRA3B or FRA7H. We
have mapped three known genes to the FRAXB
region, STS, GS1, and TLR5a. We have examined
FRAXB and four other fragile sites for instability at
both the DNA and RNA levels as a test of the
hypothesis that common fragile sites are generally
unstable in cancer cells. Our results are consistent
with the conclusion that common fragile sites, as a
class, are unstable in cancer cells, resulting in de-
letions and loss of associated gene expression.
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